
Subscribe to Goodwin Updates:
- Industry Alerts
- Blog Digests
- Firm Announcements
- Events + Webinars
Section 337 of the Tariff Act of 1930 gives the ITC broad authority to prohibit the importation and enjoin the domestic sale of imported products and components. Obtaining such comprehensive relief can provide a massive competitive edge; or, it can be fatal for a losing respondent. With so much at stake, the ITC is home to some of the highest profile business litigations in the world.
Supported by industry-leading technology, life sciences, and trade secret practices, Goodwin is equipped with one of the most experienced 337 litigation teams in the country. We have litigated over 100 Section 337 cases and have litigators with more than 30 years of experience practicing before the Commission. Our sheer breadth of experience gives us unmatched capabilities in managing the high-stakes, navigating the unique procedures, and handling the aggressive deadlines. Moreover, we are armed for trial in any given case with a team that includes multiple first-chair litigators, some of whom have participated in over 50 trials before the Administrative Law Judges (ALJs). Considering approximately 50% of cases typically go to trial within eight to ten months of complaint filing, having counsel with extensive trial experience is crucial.
Goodwin also has a deep bench. Our team of nearly 50 lawyers stay up-to-speed on every ITC rule, metric, order, and opinion that is issued by the ALJs, the Commissioners, or the Federal Circuit. At any given moment, we are prepared to staff a case, no matter how complicated, with credentialed first-chair professionals, relevant legal specialists, and befitting business sector/technology experts who are fluent in ITC practice.
Although we derive great pride from trial victories, our team works to achieve positive business outcomes before resorting to trial. Goodwin has extensive experience in issues arising post-issuance of relief, both before the Commission itself and U.S. Customs and Border Protection, which enforces the ITC’s exclusion orders. This gives us the unique ability to provide business advice on how a requested remedy will affect a business even before the remedy may issue. It also positions our team to quickly step in if a client gets an adverse ruling in an investigation where we were not counsel. Goodwin is accustomed to the ITC’s pace and assures that all litigation decisions are made with client input while providing consistent, strategic advice throughout the life of the matter(s). Complementing the firm’s legal excellence, we act first as business partners over litigators to help clients navigate the world of ITC litigation and advise on the potential business ramifications and outcomes in determining how to best proceed in an unfair competitions claim.
As a growing technology company, your prospects are exciting and your challenges are unique – from securing funding, protecting IP, and navigating the regulatory environment, to differentiating yourself in the marketplace, managing customer acquisition and scaling your business. We get it. Our dedicated team brings a comprehensive, coordinated approach that interconnects business, new technologies and the law. Our depth of experience in the private equity space along with our technology, healthcare and life sciences lawyers makes Goodwin uniquely suited to harness the breakneck pace of technology. We partner with clients to embrace the promise and potential of innovation to make a profound and lasting impact.
Succeeding in the life sciences industry is as much about strategy and execution as it is about research and development. And with the breakneck pace of technology disrupting industries on a global scale, Goodwin’s depth of experience not only in the life sciences space, but also in collaboration with our technology, healthcare, real estate and private equity lawyers, makes our team exceptionally suited to address whatever the future brings. We partner with clients to embrace the promise and potential of innovation to make a profound and lasting impact.
Goodwin’s fully integrated, globally recognized destination life sciences practice is dedicated to serving the needs of innovators and investors working collaboratively to improve patients' lives. Our team of more than 150 lawyers is devoted to life sciences companies across the entire company lifecycle, and team members are strategically located across the major life sciences hubs in the U.S., Europe and Asia.
As a growing technology company, your prospects are exciting and your challenges are unique – from securing funding, protecting IP, and navigating the regulatory environment, to differentiating yourself in the marketplace, managing customer acquisition and scaling your business. We get it. Our dedicated team brings a comprehensive, coordinated approach that interconnects business, new technologies and the law. Our depth of experience in the private equity space along with our technology, healthcare and life sciences lawyers makes Goodwin uniquely suited to harness the breakneck pace of technology. We partner with clients to embrace the promise and potential of innovation to make a profound and lasting impact.
Succeeding in the life sciences industry is as much about strategy and execution as it is about research and development. And with the breakneck pace of technology disrupting industries on a global scale, Goodwin’s depth of experience not only in the life sciences space, but also in collaboration with our technology, healthcare, real estate and private equity lawyers, makes our team exceptionally suited to address whatever the future brings. We partner with clients to embrace the promise and potential of innovation to make a profound and lasting impact.
Goodwin’s fully integrated, globally recognized destination life sciences practice is dedicated to serving the needs of innovators and investors working collaboratively to improve patients' lives. Our team of more than 150 lawyers is devoted to life sciences companies across the entire company lifecycle, and team members are strategically located across the major life sciences hubs in the U.S., Europe and Asia.